Tolerance of bradykinin-releasing drugs in patients with acquired C1 inhibitor deficiency: a case series and review of the literature.
Résumé
Bradykinin-mediated angioedema (AE) manifests as recurrent oedema of the mucosa, skin and abdominal wall, usually lasting 48 to 96 hours. It can be caused by bradykinin-releasing drugs (such as angiotensin converting enzyme inhibitors [ACEi], angiotensin receptor blockers [ARB] and dipeptidyl peptidase 4 inhibitors [DPP-4i]) or by C1-inhibitor (C1-INH) deficiency, which can be hereditary (HAE) or more rarely acquired (AAE). AAE is classically associated with lymphoid malignancies or monoclonal gammopathy [...]